Pharma stocks fall sharply as US drug pricing investigation nears completion
Media reports suggest that the US Congress investigation into price hikes, that began in October 2014, may be nearing completion, culminating into charges of price collusion against companies / individuals by the year end.
Analysts believe drug pricing probe does not warrant the 20-25% fall in stock prices. Photo: Pixabay